Efficacy and safety of rupatadine in persistent allergic rhinitis and health-related quality of life in children age 6-11 years: A randomized, double blind, placebo-controlled clinical trial.

Trial Profile

Efficacy and safety of rupatadine in persistent allergic rhinitis and health-related quality of life in children age 6-11 years: A randomized, double blind, placebo-controlled clinical trial.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2013

At a glance

  • Drugs Rupatadine (Primary)
  • Indications Perennial allergic rhinitis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Apr 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 06 Aug 2011 New trial record
    • 23 May 2011 This trial is recruiting in Spain and completed in Hungary.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top